UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,716,929 shares of the company's stock after buying an additional 206,482 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.35% of Elanco Animal Health worth $20,792,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ELAN. Blue Trust Inc. lifted its stake in Elanco Animal Health by 66.7% in the fourth quarter. Blue Trust Inc. now owns 6,615 shares of the company's stock valued at $80,000 after buying an additional 2,647 shares during the period. KBC Group NV lifted its stake in Elanco Animal Health by 264.9% in the fourth quarter. KBC Group NV now owns 323,502 shares of the company's stock valued at $3,918,000 after buying an additional 234,840 shares during the period. Institute for Wealth Management LLC. lifted its stake in Elanco Animal Health by 11.5% in the fourth quarter. Institute for Wealth Management LLC. now owns 35,516 shares of the company's stock valued at $430,000 after buying an additional 3,656 shares during the period. Spire Wealth Management raised its position in shares of Elanco Animal Health by 107.4% during the fourth quarter. Spire Wealth Management now owns 7,776 shares of the company's stock worth $94,000 after purchasing an additional 4,026 shares during the period. Finally, Jennison Associates LLC raised its position in shares of Elanco Animal Health by 1.4% during the fourth quarter. Jennison Associates LLC now owns 1,095,710 shares of the company's stock worth $13,269,000 after purchasing an additional 15,246 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ELAN shares. Piper Sandler lowered their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus upped their target price on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 19th. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Finally, UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $15.17.

Elanco Animal Health Stock Up 0.9%

Elanco Animal Health stock traded up $0.12 during trading on Thursday, hitting $13.52. 10,333,431 shares of the company were exchanged, compared to its average volume of 5,112,034. The business's 50 day moving average is $10.54 and its 200 day moving average is $11.44. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80. The company has a market capitalization of $6.71 billion, a P/E ratio of 33.80, a PEG ratio of 2.50 and a beta of 1.49. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. Elanco Animal Health's revenue was down 1.0% compared to the same quarter last year. Analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This trade represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.89% of the stock is currently owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.